

Inventor(s): Darrell Anderson et al.

Appln. No.: 09 383,916

Series Code ↑

Serial No. ↑

Filed: August 26, 1999

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1644

Examiner: P. Gambel

Atty. Dkt. P 0275716

1995-30-0233D1

M#

Client Ref

Appln. Title: Human B7.1-Specific Primatized
Antibodies and Transfectomas
Expressing Said Antibodies

Sir:

REPLY/AMENDMENT/LETTER

Date: January 10, 2002

JAN 16 2002

TECH CENTER 1600/290

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☒ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C
See **Required**
Separate Paper
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	15	**minus 20	0	x \$18/\$9 = + \$0	103/203
3. Independent Claims	1	***minus 3	0	x \$84/\$42 = + \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)				add + \$280/\$140 = + \$0	104/204
5. Original due Date: November 14, 2001		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$400/\$200 = (3 mos) \$920/\$460 = (Usable only for ≤ 2mo.OA --- 4 mos) \$1,440/\$720= (Usable only for 30 day/1mo.OA --- 5 mos) \$1,960/\$980=	+ \$400		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8. Extension Fee Attached			+ \$400		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55 + \$0 148/248		
10. If IDS attached requires Official Fee under Rule 97 (c), add			+ \$180 + \$0 126		
or if Rule 97(d) Request add			+ \$180 + \$0 126		
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$740/370 + \$0 146/246		
12. No. of additional inventions for examination per Rule 129(b).....			x \$740/370 ea + \$0 149/249		
13. Request for Continued Examination (RCE)			+ \$740/370 + \$0 1179/1279		
14. Petition fee for			+ \$0		
15. TOTAL FEE ENCLOSED =			\$400		

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 037003 0275716

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

1600 Tysons Boulevard
McLean, VA 22102
Tel: (703) 905-2000

Sig:

Fax: (703) 905-2500
Tel: (703) 905-2200

Atty/Sec: RLT/LAK

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Application No. 09/383,916

Filed: August 26, 1999

Title: HUMAN B7.1-SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS EXPRESSING SAID ANTIBODIES



Group Art Unit: 1644

Examiner: P. Gambel

14/D
gnd
1/23/02
ONE
RECEIVED

JAN 16 2002

TECH CENTER 1600/2900

* * * * *

REPLY PURSUANT TO 37 C.F.R. §1.116

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated August 14, 2001, kindly amend the above-identified application as follows.

IN THE CLAIMS:

Please cancel currently pending Claims 21-40 and substitute the following claims:

DI
--41. (New) A method of treatment that comprises blocking the B7.1/CD28 interaction in a subject in need of such treatment, by administering an anti-B7.1 antibody selected from the group consisting of antibodies having the same epitopic specificity as (i) an antibody having as its variable light sequence and variable heavy sequence the amino acid sequence of SEQ ID NO:2 and SEQ ID NO:4 respectively; (ii) an antibody having as its variable light sequence and variable heavy sequence the amino acid sequence of SEQ ID NO:6 and SEQ ID NO:8 respectively, and (iii) an antibody having as its variable light and variable heavy sequence the amino acid sequence of SEQ ID NO:10 and SEQ ID NO:12 respectively.

42. (New) The method of Claim 41 wherein the subject is one with an autoimmune disease.

Sub E1 43. (New) The method of Claim 42 wherein the autoimmune disease is psoriasis.

01/15/2002 SDUONG

00000025 09383916

01 FC:116

400.00 OP

12